Evotec’s (EVTCY) “Hold” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Evotec (OTCMKTS:EVTCY)‘s stock had its “hold” rating reissued by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Thursday, The Fly reports.

Other equities analysts have also issued reports about the stock. Citigroup lowered shares of Evotec from a “buy” rating to a “neutral” rating in a report on Friday, March 5th. Royal Bank of Canada downgraded Evotec from an “outperform” rating to a “sector perform” rating in a report on Thursday, January 28th.

Shares of Evotec stock remained flat at $$82.50 during trading on Thursday. 31 shares of the company traded hands, compared to its average volume of 930. Evotec has a 52 week low of $47.70 and a 52 week high of $90.14. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.19 and a quick ratio of 2.13. The business’s 50 day moving average price is $73.57 and its two-hundred day moving average price is $68.71. The firm has a market capitalization of $6.79 billion, a P/E ratio of 458.36 and a beta of 1.13.

About Evotec

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services.

Read More: How is an ETF different from a mutual fund?

The Fly

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.